731 related articles for article (PubMed ID: 19172514)
1. Evaluation of the Impact-R for monitoring the platelet storage lesion.
Albanyan AM; Murphy MF; Harrison P
Platelets; 2009 Feb; 20(1):1-6. PubMed ID: 19172514
[TBL] [Abstract][Full Text] [Related]
2. Use of the DiaMed Impact R to test platelet function in stored platelet concentrates.
Morrison A; Hornsey VS; Prowse CV; Macgregor IR
Vox Sang; 2007 Aug; 93(2):166-72. PubMed ID: 17683361
[TBL] [Abstract][Full Text] [Related]
3. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
Ali SF
Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
[TBL] [Abstract][Full Text] [Related]
4. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
[TBL] [Abstract][Full Text] [Related]
5. Impedance aggregometric analysis of platelet function of apheresis platelet concentrates as a function of storage time.
Glas M; Bauer JV; Eichler H; Volk T
Scand J Clin Lab Invest; 2016 Dec; 76(8):664-670. PubMed ID: 27701904
[TBL] [Abstract][Full Text] [Related]
6. Platelet function under high-shear conditions from platelet concentrates.
Jilma-Stohlawetz P; Horvath M; Eichelberger B; Koren D; Jilma B; Panzer S
Transfusion; 2008 Jan; 48(1):129-35. PubMed ID: 17894788
[TBL] [Abstract][Full Text] [Related]
7. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
Lozano M; Galan A; Mazzara R; Corash L; Escolar G
Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
[TBL] [Abstract][Full Text] [Related]
8. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
9. Quality analysis of blood components obtained by automated buffy-coat layer removal with a top & bottom system (Optipress (R)II).
Hurtado C; Bonanad S; Soler Mf; Mirabet V; Blasco I; Planelles Mf; De Miguel A
Haematologica; 2000 Apr; 85(4):390-5. PubMed ID: 10756365
[TBL] [Abstract][Full Text] [Related]
10. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
Vasconcelos E; Figueiredo AC; Seghatchian J
Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
[TBL] [Abstract][Full Text] [Related]
11. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
Singh S; Shams Hakimi C; Jeppsson A; Hesse C
Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740
[TBL] [Abstract][Full Text] [Related]
12. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis.
Procházková R; Andrýs C; Hubácková L; Krejsek J
Transfus Apher Sci; 2007 Oct; 37(2):115-23. PubMed ID: 17945536
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
Paglia G; Sigurjónsson ÓE; Rolfsson Ó; Hansen MB; Brynjólfsson S; Gudmundsson S; Palsson BO
Transfusion; 2015 Feb; 55(2):301-13. PubMed ID: 25156572
[TBL] [Abstract][Full Text] [Related]
14. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
Bux J; Müller K; Misterek J; Mueller-Eckhardt C
Beitr Infusionsther; 1990; 26():99-102. PubMed ID: 1703912
[TBL] [Abstract][Full Text] [Related]
15. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
Pietersz RN
Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
[TBL] [Abstract][Full Text] [Related]
16. Function of platelets in apheresis platelet concentrates and in patient blood after transfusion as assessed by Impact-R.
Horvath M; Eichelberger B; Koren D; Böhm A; Ay C; Jilma B; Panzer S; Jilma-Stohlawetz P
Transfusion; 2010 May; 50(5):1036-42. PubMed ID: 20051058
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
Moog R; Fröhlich A; Mayaudon V; Lin L
J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of platelet quality obtained using conventional methods or from buffy-coat and stored at room temperature].
Dzieciatkowska A; Fuskiewicz M; Ziemba-Zółowska B; Sabliński J
Acta Haematol Pol; 1994; 25(2):135-43. PubMed ID: 8067184
[TBL] [Abstract][Full Text] [Related]
19. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
[TBL] [Abstract][Full Text] [Related]
20. In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools.
Turner CP; Sutherland J; Wadhwa M; Dilger P; Cardigan R
Vox Sang; 2005 Apr; 88(3):164-71. PubMed ID: 15787726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
